Radioactive Tracer Market, By Type (Diagnostic Radioactive Tracers, Therapeutic Radioactive Tracers, and Others), By Application (Oncology, Cardiology, Neurology, Thyroid, Orthopedic, Endocrinology, and Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Nov 2023

Code : CMI6389

Pages :140

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Radioactive Tracer Market- Recent Developments:

New Product Launches:

On July 28, 2023, Curium, a leader in nuclear medicine, announced that the European Commission had granted marketing authorization for PYLCLARI (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa)
On May 27, 2021, Lantheus Holdings, Inc., a leader and fully integrated provider of innovative imaging diagnostics and targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) hasd approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY is the first and only commercially available approved PSMA PET imaging agent for prostate cancer.
In September 2020, Telix Pharmaceuticals , a pharmaceutical company, and ANMI announced the first commercial production of TLX250-CDx, a 89Zr-labelled antibody for imaging multiple myeloma

Acquisition, Collaboration and Partnerships:

On September 13, 2023, Telix Pharmaceuticals Limited., a pharmaceutical company, announced collaboration with Eckert & Ziegler, a radio tracer manufacturer, and RefleXion Medical, a pharmaceutical company to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling, quality control and storage of molecular targeting radiotracers, referred to as Bio Guides that are used in biology-guided radiotherapy (BgRT) to direct the radiation beam to indicated solid tumor cancers.
On September 7, 2023, Curium, a leader in nuclear medicine, announced that it had entered into an exclusive rights agreement with b.e. Imaging, a imaging center, for the distribution of PYLCLARI (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL), indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography in adults with prostate cancer. Under the terms of the agreement, b.e. Imaging will be responsible for obtaining marketing authorization from Swiss competent authority Swissmedic, and will have exclusive distribution rights for PYLCLARI across Switzerland.
On June 27, 2023, NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Nucleus RadioPharma, a full-service contract development and manufacturing organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies, announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225). Under terms of the agreement, NorthStar will supply its high purity, non-carrier added (n.c.a.) Ac-225 to Nucleus. Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs.
On June 21, 2023, Telix Pharmaceuticals Limited., a pharmaceutical company, announced acquisition of Lightpoint Medical, a medical device company specializing in the intra-operative detection of targeted radiopharmaceuticals, to expand into other urologic and non-urologic malignancies
In June 2021, Curium , a biotechnology company, acquired IASON GmbH, a biotechnology company, to strengthen its position in the PET imaging market. This allowed Curium to expand its offerings for neurology, oncology, and cardiology applications.
In November 2020, Telix Pharmaceuticals, a pharmaceutical company, partnered with China Grand Pharma, a pharmaceutical company, to distribute illuccix, a kidney cancer imaging agent, in China. This partnership expanded Telix' 's presence in the Chinese radiopharmaceuticals market.